At a glance
ClinicalIndex Comparison RecordN/ACompleted· 5 enrolled
Drug / intervention
Pegaptanibdrug
Likely dose
Pegaptanib 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vascular Endothelial Growth Factor (VEGF)Blockade With Intravitreal Pegaptnib in Non-Infectious Uveitic Cystoid Macular Edema (CME)
In Brief
A clinical study evaluating Pegaptanib for Uveitis and Cystoid Macular Edema. Completed, enrolled 5 participants across 1 site.
Detailed Summary
According to a recent estimate more than 280,000 people in the United States are affected by uveitis each year. This report, also estimated that uveitis is the reason for 30,000 new cases of blindness/year and up to 10 percent of all cases of blindness. The purpose of this trial is to determine the effectiveness of VEGF blockade with intravitreal pegaptanib in patients with uveitic CME.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis, Cystoid Macular Edema
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2008
Enrollment StartMar 2009
Primary CompletionNov 2011
Study CompletionMar 2012
TodayJul 2026
First PostedNov 14, 2008
Enrollment StartMar 1, 2009
Primary CompletionNov 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.6 years ago
Interventions
Pegaptanibdrug
Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.